Nuwiq FDA Approval History
FDA Approved: Yes (First approved September 4, 2015)
Brand name: Nuwiq
Generic name: antihemophilic factor (recombinant)
Dosage form: for Injection
Company: Octapharma USA, Inc.
Treatment for: Hemophilia A
Nuwiq (antihemophilic factor [recombinant]) is recombinant blood coagulation factor VIII indicated for the control and prevention of bleeding episodes in patients with hemophilia A.
Development timeline for Nuwiq
|Sep 15, 2015||Approval FDA Approves Nuwiq (Antihemophilic Factor [Recombinant]) for Hemophilia A|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.